Form 4: Fulgent Genetics' President and COO, Jian Xie, Reports Changes in Beneficial Ownership

Jian Xie, President and COO of Fulgent Genetics, reports a transaction involving common stock related to tax withholding obligations and holdings in a family trust.

Summary

• On March 1, 2025, Jian Xie, the President and COO of Fulgent Genetics, reported a transaction involving Fulgent Genetics' common stock.
• 1,481 shares were withheld to satisfy tax obligations arising from the vesting of restricted stock units granted on February 28, 2022.
• The price per share for the tax withholding was $15.45.
• Following the transaction, Mr. Xie directly owns 378,857 shares of common stock.
• Mr. Xie also indirectly owns 220,816 shares through The Hsieh Family Dynasty Trust.
• Mr. Xie serves on the investment committee of the Trust and disclaims beneficial interest except for any pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, indicating a neutral sentiment. It reports a routine transaction related to tax obligations.

Management Comments

• Mr. Xie disclaims any beneficial interest in the shares held by The Hsieh Family Dynasty Trust except with respect to any pecuniary interest therein.

Industry Context

This Form 4 filing is a routine disclosure related to insider transactions and is required by the SEC to ensure transparency in the market.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it relates to tax obligations of an executive.

Key Dates